AI Top 50 2018 – 970×90 CN


WuXi Biologics To Invest $60M For Its First Manufacturing Facility In United States

WuXi Biologics (2269.HK), an open-access biologics technology company based in China, is to invest US$60 million and hire approximately 150 employees to establish a biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility, the firm said today in an announcement.

Chinese Biotech Firm Ascletis First To File For Hong Kong IPO Under New Listing Rules

Ascletis Pharma, a Hangzhou-based biotechnology firm, has filed to list on the Hong Kong Stock Exchange, making it the first company to exploit the new and more accommodating listing rules in the city, an IPO prospectus published by the Hong Kong Stock Exchange showed. Ascletis Pharma Inc. focuses on three therapeutic areas: anti-viral, cancer and fatty liver diseases. It operates an integrated anti-viral platform focused on developing and commercializing innovative drugs against HCV, HIV and HBV. Currently, the company operates …

CDH Investments Offers Higher Bid Of $1.4B To Acquire Australian Medical Device Firm Sirtex Medical

Chinese alternative asset fund manager CDH Investments has proposed to acquire Australian medical device company Sirtex Medical Limited (ASX: SRX) for about A$1.87 billion (US$1.4 billion), according to Sirtex Medical’s announcement today. Sirtex Medical said it had received an unsolicited non-binding, indicative and conditional proposal from CDH Investments to acquire 100% of its shares for a cash price of A$33.6 per share, representing a 14.2% premium over its closing price of A$29.42. With 55.77 million shares outstanding,  Sirtex Medical is …

China’s CICC Capital Leads $286M Round In Concord Medical Services Subsidiary

Chinese specialty hospital management solution provider Concord Medical Services Holdings Limited (NYSE: CCM), has announced that CICC Capital Management Company Limited, a wholly-owned subsidiary of China International Capital Corporation Limited, will lead a strategic investment of between RMB1.5 billion (US$238.5 million) and RMB1.8 billion (US$286.16 million) in Concord Medical’s subsidiary Beijing Meizhong Jiahe Hospital Management Co., Ltd. 

Chinese Cell Therapy Firm JW Therapeutics Closes $90 Million Series A Financing

Chinese cell therapy company JW Therapeutics (Shanghai) Co., Ltd announced that it has raised a US$90 million series A found led by investors Temasek, Sequoia Capital China, and YuanMing Capital, a Beijing-based US dollar fund focusing on investments in pharmaceutical research and development, medical devices and services in both China and the U.S.